Finnegan client BioDelivery Sciences International (BDSI) prevailed over Alvogen PB Research and Development in the District of Delaware after the judge upheld claims in two patents (U.S. Patent No. 8,147,866 and U.S. Patent No. 9,901,539) related to BDSI's opioid pain medication Belbuca, which BDSI accused Alvogen of infringing. Belbuca is a chronic pain treatment that uses buccal film technology to deliver buprenorphine and is BDSI’s core product, with sales over $100 million per year.
Finnegan partner Justin Hasford said, “We are very pleased that Chief Judge Connolly found that Alvogen failed to prove its invalidity case with respect to claims 4 and 5 of the '866 patent and claims 9 and 20 of the '539 patent."
Read “Del. Judge Upholds Claims in Opioid Drug IP But Axes Others”
